AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of 225.46 billion. The enterprise value is 251.28 billion.
| Market Cap | 225.46B |
| Enterprise Value | 251.28B |
Important Dates
The next estimated earnings date is Tuesday, April 29, 2025.
| Earnings Date | Apr 29, 2025 |
| Ex-Dividend Date | Feb 20, 2025 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.06% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 32.05.
| PE Ratio | 32.05 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.62, with an EV/FCF ratio of 25.29.
| EV / Earnings | 35.72 |
| EV / Sales | 4.50 |
| EV / EBITDA | 13.62 |
| EV / EBIT | 18.87 |
| EV / FCF | 25.29 |
Financial Position
The company has a current ratio of 0.93, with a Debt / Equity ratio of 0.75.
| Current Ratio | 0.93 |
| Quick Ratio | 0.67 |
| Debt / Equity | 0.75 |
| Debt / EBITDA | 1.70 |
| Debt / FCF | 3.07 |
| Interest Coverage | 9.22 |
Financial Efficiency
Return on equity (ROE) is 17.59% and return on invested capital (ROIC) is 11.53%.
| Return on Equity (ROE) | 17.59% |
| Return on Assets (ROA) | 7.88% |
| Return on Invested Capital (ROIC) | 11.53% |
| Return on Capital Employed (ROCE) | 16.97% |
| Revenue Per Employee | 573,415 |
| Profits Per Employee | 74,602 |
| Employee Count | 94,300 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.80 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +7.67% in the last 52 weeks. The beta is 0.16, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | +7.67% |
| 50-Day Moving Average | 146.56 |
| 200-Day Moving Average | 148.40 |
| Relative Strength Index (RSI) | 48.67 |
| Average Volume (20 Days) | 1,349 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca had revenue of 54.07 billion and earned 7.04 billion in profits. Earnings per share was 4.50.
| Revenue | 54.07B |
| Gross Profit | 44.44B |
| Operating Income | 12.93B |
| Pretax Income | 8.69B |
| Net Income | 7.04B |
| EBITDA | 17.57B |
| EBIT | 12.93B |
| Earnings Per Share (EPS) | 4.50 |
Balance Sheet
The company has 5.53 billion in cash and 30.46 billion in debt, giving a net cash position of -24.94 billion.
| Cash & Cash Equivalents | 5.53B |
| Total Debt | 30.46B |
| Net Cash | -24.94B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 40.87B |
| Book Value Per Share | 26.30 |
| Working Capital | -2.04B |
Cash Flow
In the last 12 months, operating cash flow was 11.86 billion and capital expenditures -1.92 billion, giving a free cash flow of 9.94 billion.
| Operating Cash Flow | 11.86B |
| Capital Expenditures | -1.92B |
| Free Cash Flow | 9.94B |
| FCF Per Share | n/a |
Margins
Gross margin is 82.18%, with operating and profit margins of 23.91% and 13.01%.
| Gross Margin | 82.18% |
| Operating Margin | 23.91% |
| Pretax Margin | 16.07% |
| Profit Margin | 13.01% |
| EBITDA Margin | 32.49% |
| EBIT Margin | 23.91% |
| FCF Margin | 18.38% |
Dividends & Yields
This stock pays an annual dividend of 3.10, which amounts to a dividend yield of 2.10%.
| Dividend Per Share | 3.10 |
| Dividend Yield | 2.10% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 65.80% |
| Buyback Yield | -0.06% |
| Shareholder Yield | 2.04% |
| Earnings Yield | 3.12% |
| FCF Yield | 4.41% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 3.15.
| Altman Z-Score | 3.15 |
| Piotroski F-Score | n/a |